Drug Neurology

Xcopri

Payments companies reported to CMS as associated with Xcopri. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$5.8Massociated payments (2023-2025)
2,856clinicians with associated payments
1company reporting

By year

2023 $2.4M
2024 $1.7M
2025 $1.7M

Payments reported as associated with Xcopri, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $4.0M
Epilepsy $816K
Clinical Neurophysiology $174K
Neurology With Special Qualifications In Child Neurology $170K
Neurodevelopmental Disabilities (Pediatrics) $124K
Family $73K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Xcopri

These are the largest totals companies reported as associated with Xcopri. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
William Rosenfeld Chesterfield, MO Neurology (Psychiatry & Neurology) $892,564.57
Marc Kamin Oyster Bay, NY Neurology (Psychiatry & Neurology) $338,793.18
Danielle Becker Columbus, OH Epilepsy $290,967.13
Kenneth Laxer San Francisco, CA Neurology (Psychiatry & Neurology) $204,882.39
Tariq Gheith East Lansing, MI Neurology (Psychiatry & Neurology) $171,993.18
Imad Najm Cleveland, OH Neurology (Psychiatry & Neurology) $168,902.81
Gregory Connor Tulsa, OK Neurology (Psychiatry & Neurology) $154,492.74
Raman Sankar Los Angeles, CA Neurodevelopmental Disabilities (Pediatrics) $124,224.15
Michael Smith Chicago, IL Neurology (Psychiatry & Neurology) $119,366.57
Selim Benbadis Tampa, FL Neurology (Psychiatry & Neurology) $118,779.53

Prescribed Xcopri?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.